Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. - Wikidata - wikimedia - TriplyDB

Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.

Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.

http://www.wikidata.org/entity/Q33755282

about

Current concepts in the management of rheumatoid arthritis Current stage in inflammatory bowel disease: What is next?Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2 Classical and recent advances in the treatment of inflammatory bowel diseases Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia Fate of lymphocytes after withdrawal of tofacitinib treatment Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis Tofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1).Current approaches to the management of new-onset ulcerative colitis.CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm.Crystal structures of PRK1 in complex with the clinical compounds lestaurtinib and tofacitinib reveal ligand induced conformational changes.Update on Janus kinase antagonists in inflammatory bowel disease.Tofacitinib for the treatment of rheumatoid arthritis.JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy.Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes Novel hinge-binding motifs for Janus kinase 3 inhibitors: a comprehensive structure-activity relationship study on tofacitinib bioisosteres.Tyrosine kinase inhibitors induce mesenchymal stem cell-mediated resistance in BCR-ABL+ acute lymphoblastic leukemia.Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.BD750, a benzothiazole derivative, inhibits T cell proliferation by affecting the JAK3/STAT5 signalling pathway Immunosuppression by co-stimulatory molecules: inhibition of CD2-CD48/CD58 interaction by peptides from CD2 to suppress progression of collagen-induced arthritis in mice Efficient solution-phase synthesis of 4,5,7-trisubstituted pyrrolo[3,2-d]pyrimidines.Tofacitinib prevents radiographic progression in rheumatoid arthritis.JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines CP-690550 Treatment Ameliorates Established Disease and Provides Long-Term Therapeutic Effects in an SKG Arthritis Model.Current landscape for T-cell targeting in autoimmunity and transplantation.A decade of the human genome sequence--how does the medicinal chemist benefit?System-based drug discovery within the human kinome.Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.Immunomodulating options for liver transplant patients.JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis.Tofacitinib: a review of its use in adult patients with rheumatoid arthritis.New topical treatments for psoriasis.Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives.Selective JAK inhibitors.Progress toward JAK1-selective inhibitors.Discovery of 8-Amino-imidazo[1,5-a]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid Arthritis.Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside.Application of chemical biology in target identification and drug discovery.

P2860

Q26765124-804480B8-4BE5-4413-B1ED-2DD42E17C07A Q26777429-90F0E291-1ADB-4358-B320-07B2B1813A6A Q26798299-00AF2F64-9126-4091-B260-29936BEB1D2E Q26861725-42280E66-95CC-4300-A559-88A1E4E8DA35 Q28112138-B3526DEF-7BA2-415B-9737-1B1EF440077A Q28538586-72AF777E-EECF-4ED6-8C3A-8698CF74425A Q28674280-1E5204E9-4CB6-4B0A-81E8-8913760400CB Q30313903-C8473C2C-B1C0-4C02-B77A-1358C7C34051 Q33633288-471792E5-1C18-4E2F-B3A0-563AD214AD81 Q33728096-8E18CCE9-5C88-4AC0-938D-C12D5CF79053 Q33890805-87C8ECB0-6771-4F3C-AAD6-DC6A01390C44 Q34028255-6B0A2846-7DCD-4011-BC00-657FFCF1281B Q34030650-6F5DF8A7-790F-40C4-AAF3-FBB62115E25C Q34275878-A433130B-6447-456B-A2AE-91466C5E989E Q34276089-87148E6E-8AB1-45AA-930C-0233A5F551EA Q35068784-A06B232B-9EF3-4B6F-8CE3-D68751EF0D2A Q35228409-FA9E6A82-BDBF-4444-8420-16EC43306815 Q35583420-15178ED6-53BE-42AA-B327-B27E9AA9268B Q36157003-B2513731-2F30-4C40-92A1-685BC74D49DE Q36629277-819A77CD-5E53-41DC-95DB-72396D5DB8AA Q37000178-D286799D-E54C-4A4C-9506-C4A6EFC7C8CB Q37048790-4DF8D4D4-6431-4C97-AF8C-D44E9AA0C4FA Q37098047-67E97293-1E3C-45C8-8616-AC2A395DBB18 Q37148745-B6683B28-44CF-496E-964A-03F909023E40 Q37420222-7BC7D84E-4032-44B1-9D87-6A7FE77BB659 Q37900647-975A49C1-492C-4D81-AA2E-9F5570109599 Q37968558-76647EDC-02E1-4ACE-A5AC-58DD0F7B90DD Q38042726-82C9489A-5538-4AD1-8786-EED9EBF3B60F Q38042734-AF2650CD-8A6C-4F20-A30D-C1A58EB556A0 Q38044761-D402CF20-9932-4528-8606-3EBD72019046 Q38065100-0DF127CA-AE6E-4DAA-97AA-EEA5150FF3C6 Q38097494-6168AF0F-A060-4191-AED7-5C26A0DB9C3B Q38110227-9BC08D81-6FB8-452E-8D1F-F7A120DE1BD0 Q38176057-81CDB65C-075D-4C31-8691-B12C0CA2AAB5 Q38251801-E57B3643-705B-49E1-A18A-56AA38D2071F Q38261371-6A68FC86-C5B9-455C-9632-7D001F0794CF Q38357083-12E4FA9D-F8D5-445C-ABFF-E90A3F758C7A Q38434264-1B2EEE2F-F00C-4C8E-85F7-6BEF933F0E6D Q38543700-8959E2B8-56D2-4789-97CB-C015738ADDB0 Q38560888-AC22FECC-4028-4B4A-A317-6DCF03DB7025

P2860

Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.

http://www.wikidata.org/entity/Q33755282

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Discovery of CP-690,550: a pot ...... nd organ transplant rejection.

@ast

Discovery of CP-690,550: a pot ...... nd organ transplant rejection.

@en

type

label

Discovery of CP-690,550: a pot ...... nd organ transplant rejection.

@ast

Discovery of CP-690,550: a pot ...... nd organ transplant rejection.

@en

prefLabel

Discovery of CP-690,550: a pot ...... nd organ transplant rejection.

@ast

Discovery of CP-690,550: a pot ...... nd organ transplant rejection.

@en

P1433

Q33755282-841D06C5-44FC-4657-9F36-F579C3CCAA00

P1476

Q33755282-617E9CE4-75E3-4BE6-B3D8-6B3047A897A9

P2093

Q33755282-038523B2-B8A4-488E-8DDC-B14F53FA4CE8

Q33755282-06B96778-72BF-4572-B477-FCA9DBDDDD0C

Q33755282-0CA3F2E1-DB6F-4469-98E2-A5FC3D6398BA

Q33755282-1311E6F2-5444-4803-9550-C62144D92977

Q33755282-18D9FAC6-5274-43FF-8719-889BB4030E92

Q33755282-1AAA4B09-FBA7-4762-A891-317E5819038B

Q33755282-3B5B1576-00CC-40B5-A188-56BBDC7C67D2

Q33755282-407EDD81-C97C-4205-A40E-706D30EFAE56

Q33755282-672589DC-547D-4F74-A131-2DBD433D2CDC

Q33755282-6A4F7ADE-5305-4A52-87AE-15E78413BC47

P304

Q33755282-658E57CC-5253-4013-9827-92689DD0E4AA

P31

Q33755282-6DBB0CFD-B04F-4221-BD84-70F8E7A97BB5

P356

Q33755282-7ED51D24-998B-415E-B3FA-6D919BDD457C

P407

Q33755282-8ED01701-C350-4826-A9AE-B1FF7FABC3A3

P433

Q33755282-E171A21C-E40C-43AE-B17E-F07AF31F5434

P478

Q33755282-48EE4FDD-C5D6-4629-8D22-EEB75F553893

P577

Q33755282-4318FEC4-E88B-4045-B6A8-531A5F2C2BF3

P698

Q33755282-6A812A6C-FFEC-467C-9572-CAA2FD0A337B

P921

Q33755282-E62505D0-C14C-4653-B5EE-79301515CCFD

P356

P1433

Journal of Medicinal Chemistry

P1476

Discovery of CP-690,550: a pot ...... nd organ transplant rejection.

@en

P2093

Bret D Perry

http://www.w3.org/2001/XMLSchema#string

Brett M Lillie

http://www.w3.org/2001/XMLSchema#string

Chakrapani Subramanyam

http://www.w3.org/2001/XMLSchema#string

Chang Shang-Poa

http://www.w3.org/2001/XMLSchema#string

Craig Kent

http://www.w3.org/2001/XMLSchema#string

David A Whipple

http://www.w3.org/2001/XMLSchema#string

Eileen A Elliott

http://www.w3.org/2001/XMLSchema#string

Elizabeth M Kudlacz

http://www.w3.org/2001/XMLSchema#string

Jeffrey M Casavant

http://www.w3.org/2001/XMLSchema#string

Jianmin Sun

http://www.w3.org/2001/XMLSchema#string

P304

8468-8484

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM1004286

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21105711

http://www.w3.org/2001/XMLSchema#string

P921

tofacitinib citrate